Opticom has signed an international cooperation agreement with pharmexx Nordic, part of pharmexx GmbH – a world leading consulting company within contract sales in the Medical & Healthcare sector.
The agreement entails a joint offer by Opticom and pharmexx of prepared integrated solutions, tailor made for Medical & Healthcare companies. Using our vast expertise within this business we are able to help our clients to establish their products and services in the global marketplace – both faster and more cost effectively. The pace of change within the Medical & Healthcare sector has increased and will continue to do so, both globally as well as locally. This sector is undergoing constant change and in order to be competitive, companies must both foresee these changes and achieve a deeper understanding of them.
Opticom’s and pharmexx’ daily commercial operations include actively monitoring and following-up on events and trends in order to understand and foresee what is going on locally, regionally, and globally. All aimed at gaining increased insight and knowledge to help our clients make better business decisions.
“By uniting both our companies’ competences in a strategic alliance we are now able to offer our clients wider service and deeper analyses prior to product launches and the development of market plans” says Göran Olsson, CEO for pharmexx Nordic.
“Our clients will benefit from a simplified process in creating an integrated business plan, based on the conducted market analysis. Clients will save both time and money thanks to a complete solution where we cooperate in well established, highly specialised teams with vast business experience” says Carl Michael Bergman, CEO at Opticom International Research.
In the autumn of 2009, Opticom and pharmexx Nordic will jointly launch an integrated consulting product called “Wow” – the effective business guide with market insight for better product launches. This product is a platform for decision making which includes market insights and a complete business plan over five years within selected market segments and target groups. “Wow” consists of the following parts:
1. Customer segment prioritising
2. Description of markets and its dynamic
3. Presentation of market pattern and behaviour, including trends
4. Description of set of regulations, alternatives and patient flow
5. Direction of marketing and communication
6. Launching costs
7. Organisational proposal
8. P & L from three to five years
For more information, please contact:
Carl Michael Bergman, CEO, Opticom International Research AB
Mobil: +46 708-39 90 02
Göran Olsson, CEO, pharmexx Nordic AB
Mobil: +46 706-69 77 86